

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000154

International filing date: 17 January 2005 (17.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/536,860
Filing date: 16 January 2004 (16.01.2004)

Date of receipt at the International Bureau: 28 February 2005 (28.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PCT/GB2005/000154

PA 1275555

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


January 24, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/536,860

FILING DATE: January 16, 2004

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



Trudie Wallace
TRUDIE WALLACE

Certifying Officer

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(b)(2)

CERTIFICATE OF MAILING BY EXPRESS MAIL UNDER 37 C.F.R. §1.10

NUMBER OF EXPRESS MAIL MAILING LABEL **EV301975130US** DATE OF DEPOSIT WITH POSTAL SERVICE **January 16, 2004**

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office" Addressee" service under 37 C.F.R. §1.10 on the date indicated above, and is addressed to Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jane C. Bogan
Name of Person Mailing Paper or Fee

Jane C. Bogan
Signature of Person Mailing Paper or Fee

Docket No. **0380-
P03354US0**

Type a plus sign (+) inside this box +

INVENTOR(S)/APPLICANT(S)			
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
ANSELL	Keith	Hugh	London, United Kingdom
TITLE OF THE INVENTION (200 characters max)			
METHODS AND MEANS OF RHOMBOID SCREENING			
CORRESPONDENCE ADDRESS			
CUSTOMER NUMBER 000110 Telephone (215) 563-4100 Facsimile (215) 563-4044 Direct Inquiries to: Kathleen D. Rigaut, Ph.D., J.D.			
STATE PA	ZIP CODE 19103	COUNTRY US	
ENCLOSED APPLICATION PARTS (check all that apply)			
<input checked="" type="checkbox"/> Specification		Number of Pages <u>39</u>	
<input checked="" type="checkbox"/> Claims		Number of Claims <u>49</u>	
<input checked="" type="checkbox"/> Drawings(s)		Number of Sheets <u>5</u> Other (specify) _____	
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)			
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.		PROVISIONAL FILING FEE AMOUNT(S) \$ 160.00	
<input type="checkbox"/> In the event a fee is required and not enclosed, or the check is improper, or the fee calculation is in error, the Commissioner is hereby authorized to charge any payment to the account of the undersigned attorneys, Deposit Account No. 04-1406. A duplicate copy of this sheet is enclosed.			

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No

☐ Yes, the name of the U.S. Government agency contract number is: _____

Respectfully submitted
DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By *Patrick J. Hagan*
Patrick J. Hagan, Esq.
PTO Reg. No. 27,643

☐ Additional inventors are being named on separately numbered sheets attached hereto

METHODS AND MEANS OF RHOMBOID SCREENING

This invention relates to methods of screening for compounds which modulate the activity of rhomboid proteins. Modulatory compounds may be useful in a range of therapeutic applications.

Rhomboids are a conserved family of intermembrane serine proteases which are involved in controlling diverse biological functions (Urban and Freeman Mol Cell. 2003 Jun; 11(6): 1425-34, Urban, S. et al (2002) EMBO J. 21, 4277-4286, Urban, S. et al (2002) Current Biology 12, 1507-1512). Screening methods suitable for use in high throughput formats are an important step in the development of therapeutics which target rhomboids.

Known methods of screening for rhomboid activity lack sensitivity, have a low signal to background ratio and are unsuitable for use in high-throughput formats (Urban et al (2003) supra; WO02/093177). In particular, rhomboid-independent proteolysis leads to sensitivity and background problems and often needs to be suppressed with inhibitors (e.g. batimastat; British Biotech).

Transmembrane proteins, including, for example, TNF α , TGF α and other EGF receptor ligands, are substrates for metalloproteases (MPs), including ADAM (a disintegrin and metalloprotease) family MPs, such as TACE (tumour necrosis factor α convertase). These enzymes cleave their substrates to release the extracellular domain in a process known as ectodomain shedding. Ectodomain shedding is sensitive to metalloprotease inhibitors such as batimastat, which contain a hydroxamate group that acts as a zinc-binding group. (Pandiella, A. & Massague, J.

(1991) *J Biol Chem* 266, 5769-73, Arribas, J. et al (1997) *J Biol Chem* 272, 17160-5, Wang, X. et al (2003) *Mol Endocrinol* 17, 1931-43, Seals, D. F. & Courtneidge, S. A. (2003). *Genes Dev* 17, 7-30).

5

No precise consensus has emerged for the cleavage determinant of ADAM family MPs. However a consistent feature is that the cleavage determinant is generally located in a stalk region between the membrane and an initial globular extracellular subdomain (Wang, X. et al (2002) *J Biol Chem* 277, 50510-9). For TGF α , 14 juxtamembrane residues are sufficient to confer shedding and a lack of secondary structure in the juxtamembrane region may confer susceptibility to sheddases rather than a specific primary sequence motif (Arribas et al. (1997) supra) . The cleavage of the extracellular domain of GH binding protein by MP-mediated sheddase has been reported to occur at a position 9 residues outside the transmembrane domain (Wang et al. 2003).

20

The present inventors have developed improved methods of screening for rhomboid modulators which reduce the problems associated with rhomboid-independent proteolysis.

25

A first aspect of the invention provides a method for identifying and/or obtaining a modulator of a rhomboid polypeptide, which method comprises:

(a) contacting a rhomboid polypeptide and a substrate polypeptide in the presence of a test compound and one or more non-rhomboid proteases,

30

wherein said substrate polypeptide comprises a core domain which includes a rhomboid cleavable transmembrane domain (TMD) sequence and a tag sequence, the core

domain sequence not being susceptible to cleavage by the one or more non-rhomboid proteases, and;

(b) determining the presence in said medium of a polypeptide fragment comprising said tag sequence.

5

Cleavage of the substrate polypeptide to generate the fragment may be determined in the presence and absence of test compound. A difference in cleavage in the presence of the test compound relative to the absence of test
10 compound may be indicative of the test compound being a modulator of rhomboid protease activity.

The rhomboid and substrate polypeptides may be contacted under conditions wherein, in the absence of the test
15 compound, the rhomboid polypeptide cleaves the TMD sequence of the substrate polypeptide to produce a polypeptide fragment comprising the tag sequence. The presence of such a fragment in the medium is then detected by means of the tag sequence.

20

Non-rhomboid proteases may be soluble or membrane bound and may include metalloproteases (MPs) including ADAM metalloproteases, such as TACE.

25 Non-rhomboid proteases cleave the substrate polypeptide to produce polypeptide fragments. However, whilst rhomboid proteases cleave within the TMD, non-rhomboid proteases cleave outside the core domain (i.e. upstream of the tag sequence) and the proteolytic fragments thus
30 produced lack the tag sequence. The position of the tag within the substrate polypeptide thus allows discrimination between non-rhomboid and rhomboid cleavage events.

The rhomboid polypeptide and the substrate polypeptide are preferably membrane-bound. The polypeptides may be co-expressed within a cell, for example a yeast, insect or mammalian cell, for example a CHO, HeLa or COS cell.

- 5 The polypeptide fragment is preferably soluble and is secreted into the medium after cleavage.

The core domain is preferably a chimeric sequence which comprises a rhomboid cleavable TMD and a heterogenous tag
 10 sequence. The tag sequence may be positioned within the TMD or, more preferably, upstream of the TMD i.e. positioned within the core domain closer to the N terminal or extracellular/luminal domain than the TMD. The tag sequence is preferably an affinity tag, i.e. a
 15 heterogeneous peptide sequence which forms one member of a specific binding pair. Polypeptides containing the tag may be detected by determining the binding of the other member of the specific binding pair to the polypeptide. In some preferred embodiments, the tag sequence may form
 20 an epitope which is bound by an antibody molecule.

A tag sequence may consist of at least 2, 4, 6, or 8 amino acid residues. A tag sequence may further consist of 25 or less, 20 or less, 15 or less or preferably 10 or
 25 less amino acid residues.

Various suitable tag sequences are known in the art, including, for example, MRGS(H)₆, DYKDDDDK (FLAGTM), T7-, S- (KETAAAKFERQHMDS), poly-Arg (R₅₋₆), poly-His (H₂₋₁₀),
 30 poly-Cys (C₄) poly-Phe(F₁₁) poly-Asp(D₅₋₁₆), Strept-tag II (WSHPQFEK), c-myc (EQKLISEEDL), Influenza-HA tag (Murray, P. J. et al (1995) *Anal Biochem* **229**, 170-9), Glu-Glu-Phe tag (Stammers, D. K. et al (1991) *FEBS Lett* **283**, 298-302), Tag.100 (Qiagen; 12 aa tag derived from mammalian

MAP kinase 2), Cruz tag 09™ (MKAEFRRQESDR, Santa Cruz Biotechnology Inc.) and Cruz tag 22™ (MRDALDRLDRLA, Santa Cruz Biotechnology Inc.). Known tag sequences are reviewed in Terpe (2003) Appl. Microbiol. Biotechnol. 60
5 523-533.

In preferred embodiments, a poly-His tag such as MRGS(H)₆ is used.

10 The tag sequence is preferably positioned adjacent to the rhomboid cleavable TMD sequence within the core domain. For example, the tag sequence may be positioned 10 amino acid residues or less, 5 amino acid residues or less or 2 amino acid residues or less upstream of said TMD. In some
15 embodiments, the tag sequence may be directly linked to said TMD (i.e. immediately upstream of the TMD).

In other embodiments, the tag sequence may be positioned within the TMD. A suitable intramembrane tag sequence may
20 comprise a hydrophobic amino acid sequence.

The substrate polypeptide may comprise any TMD which is proteolytically cleaved by a rhomboid polypeptide. Such TMDs are readily identified using standard techniques.
25

In some preferred embodiments, a rhomboid cleavable TMD may have a lumenal portion which has the same conformation within the membrane as Spitz (Q01083) residues 140-144 (IASGA) or more preferably Spitz residues 138-144
30 (ASIASGA), or the equivalent residues in a different rhomboid ligand, such as Gurken (P42287), Keren (AAF63381), Mgm1 (YOR211C), Ccp1 (YKR066C) or mammalian thrombomodulin, for example mouse thrombomodulin (NP_033404), rabbit (*Oryctolagus cuniculus*; AAN15931);

rat (*Rattus norvegicus*; NP_113959), cow (*Bos Taurus*; AAA30785) or human thrombomodulin (AAH533357). Other rhomboid ligands include EGFR ligands, examples of which are shown in Table 2.

5

The luminal portion of a rhomboid cleavable TMD may, for example, comprise or consist of Spitz residues 140-144 (IASGA), more preferably Spitz residues 138-144 (ASIASGA), or the equivalent residues in a different rhomboid ligand, such as Gurken, Keren, Mgm1, Ccp1 or thrombomodulin.

In some embodiments, the rhomboid cleavable TMD may be an rhomboid ligand TMD, for example a TMD from a ligand, such as Gurken, Keren, *S. cerevisiae* polypeptides MGM1/YOR211C and CCP1/YKR066C or mammalian thrombomodulin, or a variant or allele of any of these. In some preferred embodiments, a Spitz TMD may be used.

A variant or allele of a rhomboid ligand may include a polypeptide modified by varying the amino acid sequence of the protein, e.g. by manipulation of the nucleic acid encoding the protein or by altering the protein itself. Such variants of the natural amino acid sequence may involve one or more of insertion, addition, deletion or substitution of one or more amino acids, which may be without fundamentally altering the susceptibility of the polypeptide to proteolytic cleavage by a rhomboid polypeptide.

30

A TMD from a variant or allele of a rhomboid ligand may have a luminal portion which has the same conformation within the membrane as the rhomboid ligand. In some embodiments, the TMD of a variant or allele of a rhomboid

ligand may consist of a sequence which has the having greater than about 50% sequence identity with the TMD sequence of the rhomboid ligand, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, or greater than about 95%. The sequence may share greater than about 70% similarity with the TMD sequence of the rhomboid ligand, greater than about 80% similarity, greater than about 90% similarity or greater than about 95% similarity.

10

The substrate polypeptide may comprise a cytoplasmic domain downstream (i.e. towards the C terminal) of the core domain. In some embodiments, the cytoplasmic domain may be the cytoplasmic domain of a rhomboid ligand, for example, a TGF α cytoplasmic domain.

15

In some preferred embodiments, cytoplasmic domain may be the cytoplasmic domain of thrombomodulin or a variant or allele thereof. When the substrate polypeptide comprises such a cytoplasmic domain, the rhomboid polypeptide is preferably a RHBDL2 polypeptide, as described below.

20

An variant or allele of the cytoplasmic domain of thrombomodulin may comprise or consist of an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% sequence identity with the amino acid sequence of the cytoplasmic domain (residues 540-575) of a mammalian thrombomodulin, for example mouse thrombomodulin (NP_033404) or human thrombomodulin (AAH533357).

30

Amino acid identity and similarity are generally defined with reference to the algorithm GAP (Genetics Computer Group, Madison, WI). GAP uses the Needleman and Wunsch

algorithm to align two complete sequences that maximizes the number of matches and minimizes the number of gaps. Generally, the default parameters are used, with a gap creation penalty = 12 and gap extension penalty = 4. Use
5 of GAP may be preferred but other algorithms may be used, e.g. BLAST or TBLASTN (which use the method of Altschul et al. (1990) J. Mol. Biol. 215: 405-410), FASTA (which uses the method of Pearson and Lipman (1988) PNAS USA 85: 2444-2448), or the Smith-Waterman algorithm (Smith and
10 Waterman (1981) J. Mol Biol. 147: 195-197), generally employing default parameters.

Similarity allows for "conservative variation", i.e. substitution of one hydrophobic residue such as
15 isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. Particular amino acid sequence variants or alleles may differ from a known sequence as
20 described herein by insertion, addition, substitution or deletion of 1 amino acid, 2, 3, 4, 5-10, 10-20 20-30, 30-50, or more than 50 amino acids.

Sequence identity and similarity are generally determined
25 over the full-length of the sequence unless context dictates otherwise.

The substrate polypeptide may also comprise an extracellular domain upstream (i.e. towards the N
30 terminal) of the core domain. The extracellular domain may comprise a detectable label. Suitable detectable labels include fluorescent proteins such as green fluorescent protein (GFP), luciferase, alkaline phosphatase and red, yellow, cyan and enhanced versions

thereof. Other suitable labels include β -galactosidase, β -lactamase and β -glucuronidase. These labels allow convenient detection of the soluble cleaved product and are particularly useful in automated assays.

5

In some preferred embodiments, the detectable label is secreted alkaline phosphatase. The presence of a secreted alkaline phosphatase label may be detected by conventional techniques. For example, SEAP may be
10 detected using a chemiluminescent substrate CSPD[®] (Tropix, Bedford, MA, USA) (Bronstein, I. et al . (1994). *Anal Biochem* **219**, 169-81) Fluorogenic substrates e.g. MUP, (Molecular Probes) may also be used, although these are less sensitive. Standard alkaline phosphatase substrates,
15 such as p-nitrophenyl phosphate, have still lower sensitivity.

The extracellular domain may also comprise an N terminal signal sequence which directs the secretion of the
20 cleaved polypeptide fragment from the host cell, for example a secreted alkaline phosphatase signal sequence.

A polypeptide substrate may be a chimeric polypeptide comprising sequence from two or more rhomboid ligands
25 along with the tag sequence, for example a chimeric ligand may comprise the transmembrane domain of a first rhomboid ligand in a core domain adjacent to a heterogeneous tag sequence and the intracellular and/or extracellular domains of a second rhomboid ligand.

30

In some embodiments, a chimeric ligand may comprise a cytoplasmic domain from a first rhomboid ligand and a rhomboid cleavable TMD from a second rhomboid ligand, in addition to a heterogeneous tag.

A suitable rhomboid polypeptide for use in the present methods may have a sequence shown in Table 1.

- 5 For example, the rhomboid polypeptide may be selected from the group consisting of *Drosophila* Rhomboid 1, *Drosophila* Rhomboid 2, *Drosophila* Rhomboid 3, *Drosophila* Rhomboid 4, Human RHBDL-1, Human RHBDL-2 and Human RHBDL-3, *E. coli* glgG, *B. subtilis* ypqP, *P. stuartii* A55862
10 gene product, *P. aeruginosa* B83259 gene product, *S. cerevisiae* YGR101w and *S. cerevisiae* YPL246c. Other suitable rhomboids may be identified using conventional database searching methods.
- 15 In preferred embodiments, the rhomboid polypeptide is selected from Human RHBDL-1, Human RHBDL-2 and Human RHBDL-3.

Rhomboid polypeptides preferably comprise catalytic
20 residues R152, G215, S217 and H281, more preferably catalytic residues W151, R152, N169, G215, S217 and H281. The presence of these conserved residues may be used to identify rhomboid polypeptides.

- 25 Preferably, a rhomboid polypeptide comprises at least 5 TMDs, with residues N169, S217 and H281 each occurring in different TMD at about the same level in the lipid membrane bilayer. Preferably, a rhomboid polypeptide also comprises a GxSG motif, as described above.

30

Rhomboid amino acid residues are described herein with reference to their position in the *Drosophila* Rhomboid-1 sequence. It will be appreciated that the equivalent residues in other rhomboid polypeptides may have a

different position and number, because of differences in the amino acid sequence of each polypeptide. These differences may occur, for example, through variations in the length of the N terminal domain. Equivalent residues
5 in Rhomboid polypeptides are easily recognisable by their overall sequence context and by their positions with respect to the rhomboid TMDs.

Rhomboid polypeptides are also characterised by the
10 presence of a rhomboid homology domain, as defined by the PFAM protein structure annotation project (Bateman A. et al (2000) The Pfam Protein Families Database Nucl. Acid. Res. 28 263-266). The Pfam rhomboid homology domain is built from a Hidden Markov Model (HMM) using 26 rhomboid
15 sequences as a seed. The Pfam 'rhomboid' domain has the pfam specific accession number PF01694.

The rhomboid polypeptide may comprise an ER (endoplasmic reticulum) retention signal. The KDEL ER retention
20 signal is not found in natural rhomboid polypeptides and directs the expressed rhomboid polypeptide to be retained the ER (endoplasmic reticulum) rather than the Golgi apparatus.

25 The term "heterologous" may be used to indicate that the nucleic acid sequence in question has been introduced into a nucleic acid construct, vector or cell using genetic engineering, i.e. by human intervention, and is not naturally associated with the nucleic acid sequence
30 of the construct, vector or cell.

Polypeptide fragments which retain the activity of the full-length protein may be generated and used in the methods described herein.

The presence in the medium of rhomboid-cleaved polypeptide fragments comprising the tag sequence may be determined by any convenient technique, for example,
5 Western blotting, capture ELISA, affinity chromatography or other chromatographic method or methods followed by SDS PAGE and/or reporter assay.

In some preferred embodiments, the presence of the
10 soluble polypeptide fragment in the medium may be determined by;
(a) contacting the medium with a specific binding member which binds to the tag sequence, and
(b) determining binding of the soluble polypeptide
15 fragment to the specific binding member.

Suitable specific binding members include an antibody molecule which binds to the tag sequence or an immobilised metal chelate, which binds, for example, to a
20 polyHis tag.

Binding of specific binding members, such as antibody molecules, may be determined by any appropriate means. Detection of individual label molecules is one
25 possibility. For example, the binding of the polypeptide fragment to the specific binding member may be determined by detecting the level or amount of bound label.

The label may directly or indirectly generate a
30 detectable, and preferably measurable, signal. The level or amount of said label bound to the specific binding member may, for example, be determined by contacting the label with a substrate which reacts with the label to produce a signal.

In some preferred embodiments, the substrate reacts with the label to produce light. For example, the reaction of the label and the substrate may produce luminescence. The
5 subsequent light emission may be measured, for example using a luminometer.

The detectable label may be linked to the specific binding pair member or more preferably to the polypeptide
10 fragment by a direct or indirect, covalent, e.g. via a peptide bond, or non-covalent linkage. Suitable labels may include a fluorophore such as FITC or rhodamine, a radioisotope, or a non-isotopic-labelling reagent such as biotin or digoxigenin; polypeptides containing biotin may
15 be detected using "detection reagents" such as avidin conjugated to any desirable label such as a fluorochrome. In preferred embodiments, a detectable polypeptide label such as green fluorescent protein (GFP), luciferase or alkaline phosphatase may be used. A polypeptide label is
20 preferably comprised within the extracellular domain of the substrate polypeptide.

In some embodiments, the binding of an antibody or other specific binding pair member to a tag-containing
25 polypeptide fragment may be detected using a second antibody. The second antibody may bind to the specific binding pair member (e.g. the first antibody), or may bind to a different region of the same polypeptide fragment, for example in a sandwich assay. Depending on
30 the assay format employed, the second antibody may be immobilised or labelled with a detectable label.

The mode of determining binding to the specific binding member is not a feature of the present invention and

those skilled in the art are able to choose a suitable mode according to their preference and general knowledge.

Specific binding pair members, such as antibody
5 molecules, which bind specifically to a tag sequence may be produced using techniques which are conventional in the art. Many suitable specific binding pair members are available commercially (for example, RGS/His tag antibody (Qiagen), Tetra, penta- and hexa- his antibodies
10 (Qiagen), Tag.100 antibody (Qiagen), HA tag antibody (Santa Cruz Biotechnology Inc.), 9E10 antibody against c-myc tag (Santa Cruz Biotechnology Inc), Cruz tag antibodies (Santa Cruz Biotechnology Inc.) and Anti-FLAG tag antibody (Sigma Aldrich)).

15

A specific binding member, such as an antibody, for use in a method described herein may be immobilised or non-immobilised i.e. free in solution.

20 An antibody or other specific binding pair member may be immobilised, for example, by attachment to an insoluble support. The support may be in particulate or solid form and may include a plate, a test tube, beads, a ball, a filter or a membrane. An antibody may, for example, be
25 fixed to an insoluble support that is suitable for use in affinity chromatography. Methods for fixing antibodies to insoluble supports are known to those skilled in the art.

30 A convenient way of producing rhomboid and substrate polypeptides for use in methods described herein is to express nucleic acid encoding them, by use of the nucleic acid in an expression system. This may conveniently be achieved by growing a host cell in culture, containing

one or more expression vectors, under appropriate conditions that cause or allow expression of the polypeptides e.g. in eukaryotic cells such as COS or CHO cells or in prokaryotic cells such as *E. coli*.

5

The amount of test substance or compound which may be used in a method described herein will normally be determined by trial and error depending upon the type of compound used. Typically, from about 0.01nM to 40µM concentrations of putative inhibitor compound may be used, for example from 1nM to 40 µM. When cell-based assays are employed, the test substance or compound is desirably membrane permeable in order to access the Rhomboid polypeptide.

15

Test compounds may be natural or synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used.

20

Combinatorial library technology (Schultz, JS (1996) Biotechnol. Prog. 12:729-743) provides an efficient way of testing a potentially vast number of different substances for ability to modulate activity of a polypeptide. Prior to or as well as being screened for modulation of activity, test substances may be screened for ability to interact with the Rhomboid polypeptide, e.g. in a yeast two-hybrid system (which requires that both the polypeptide and the test substance can be expressed in yeast from encoding nucleic acid). This may be used as a coarse screen prior to testing a substance for actual ability to modulate Rhomboid activity.

30

One class of putative inhibitor compounds can be derived from a Rhomboid polypeptide and/or a rhomboid ligand TMD. Membrane permeable peptide fragments of from 5 to 40 amino acids, for example, from 6 to 10 amino acids may be tested for their ability to disrupt such interaction or activity. Especially preferred peptide fragments comprise residues 141 to 144 (ASGA) of the Spitz protein, residues 140-144 (IASGA) or residues 138-144 (ASIAGA), or the equivalent regions of other rhomboid ligands.

10

The inhibitory properties of a peptide fragment as described above may be increased by the addition of one of the following groups to the C terminal: chloromethyl ketone, aldehyde and boronic acid. These groups are transition state analogues for serine, cysteine and threonine proteases. The N terminus of a peptide fragment may be blocked with carbobenzyl to inhibit aminopeptidases and improve stability (Proteolytic Enzymes 2nd Ed, Edited by R. Beynon and J. Bond Oxford University Press 2001). Two compounds TPCK and 3, 4-DCI have been shown to inhibit Rhomboid activity. Although these compounds are broad-spectrum serine protease inhibitors, they represent examples of lead compounds for the rational design of specific Rhomboid inhibitors.

25

Other candidate inhibitor compounds may be based on modelling the 3-dimensional structure of a polypeptide or peptide fragment and using rational drug design to provide potential inhibitor compounds with particular molecular shape, size and charge characteristics. Suitable techniques are well known in the art and are described in more detail below.

30

- A method as described herein may comprise the step of identifying a test compound as an agent which modulates rhomboid activity, for example by determining an increase or decrease in the amount of rhomboid directed substrate polypeptide cleavage in the presence relative to the absence of the compound. The compound may be an inhibitor (antagonist) or enhancer (agonist) rhomboid directed substrate polypeptide cleavage
- 10 Following identification of a compound that modulates rhomboid activity, the compound may be investigated further, in particular for its ability to modulate one or more rhomboid-mediated cellular activities.
- 15 Following identification of a substance which modulates or affects polypeptide activity, the substance may be investigated further. For example, a method may further comprise the step of determining the ability of said test compound to inhibit the infectivity or virulence of a
- 20 microbial pathogen. This may, for example, comprise determining the expression of toxic virulence factors in the presence and absence of test compound. A microbial pathogen may include yeasts and pathogenic bacteria such as *Providencia stuartii*, *E. coli* 0157 and *Pseudomonas*
- 25 *aeruginosa*.

A compound identified as a rhomboid modulator may be isolated and/or purified, or alternatively it may be synthesised using conventional techniques of recombinant expression or chemical synthesised. The compound may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals for the treatment of

35 disorders as described below. Methods of the invention

may thus comprise formulating said test compound in a pharmaceutical composition with a pharmaceutically acceptable excipient, vehicle or carrier for therapeutic application, as discussed further below.

5

A method of making a pharmaceutical composition may comprise,

identifying a compound as a modulator of Rhomboid activity using a method described herein,

10 synthesising, preparing or isolating said modulator and,

admixing the modulator with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients to formulate or produce said

15 composition; and, optionally,

determining the activity of a Rhomboid polypeptide as described herein in the presence of said composition.

Compounds identified as rhomboid modulators may be
20 modified to optimise activity or other properties such as increased half-life or reduced side effects upon administration to an individual.

The modification of a known pharmacologically active
25 compound to improve its pharmaceutical properties is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesise or where it is unsuitable for a particular
30 method of administration, e.g. peptides are not well suited as active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal. The design, synthesis and testing of modified active compounds, including mimetics, may be

used to avoid randomly screening large number of molecules for a target property. Whilst TPCK and 3, 4-DCI have been shown to inhibit Rhomboid, these compounds lack specificity and so are liable to produce undesirable side-effects, if used therapeutically. They may however represent "lead" compounds for the development of mimetics with improved specificity.

There are several steps commonly taken in modifying a compound such as TPCK, 3, 4-DCI, or Spitz transmembrane fragments, which has a given target property. Firstly, the particular parts of the compound that are critical and/or important in determining the target property are determined. In the case of a peptide, this can be done by systematically varying the amino acid residues in the peptide, e.g. by substituting each residue in turn.

The essential catalytic residues of polypeptides of the Rhomboid family are highly conserved and equate to residues N169, G215, S217, H281, W151 and R152 of the *Drosophila* Rhomboid-1 sequence. The essential residues required for cleavage by Rhomboid are residues A141, S142, G143 and A144 of the Spitz sequence or their equivalent in other rhomboid ligands. Other important residues include residues A138 S139 and I140 of the Spitz sequence or their equivalent in other rhomboid ligands.

These parts or residues constituting the active region of the compound are known as its "pharmacophore". The information provided herein regarding the pharmacophore of the Rhomboid family and its substrate allow their structures to be modelled according their physical properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources, e.g.

spectroscopic techniques, X-ray diffraction data and NMR. Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore, rather than the bonding between atoms) and other techniques can be
5 used in this modelling process.

In a variation of this approach, the three-dimensional structure of the Rhomboid polypeptide and its substrate TMD are modelled. This can be especially useful where
10 the ligand and/or binding partner change conformation on binding, allowing the model to take account of this the design of the mimetic.

A template molecule is then selected onto which chemical
15 groups which mimic the pharmacophore can be grafted. The template molecule and the chemical groups grafted on to it can conveniently be selected so that the modified compound is easy to synthesise, is likely to be pharmacologically acceptable, and does not degrade in
20 vivo, while retaining the biological activity of the lead compound. Modified compounds found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. For example, mimetics which model the three-dimensional
25 conformation of the Rhomboid recognition domain of a rhomboid ligand (for example, Spitz residues 140-144: IASGA, or more preferably residues 138-144: ASIASGA) may be used to screen for a compound which binds and inhibits a Rhomboid polypeptide. Such mimetics may include peptide
30 chloromethyl ketone analogues of the Rhomboid-binding domain of a rhomboid ligand, for example, a Spitz analogue comprising the IASGA or ASIASGA sequence.

Further optimisation or modification can then be carried out to arrive at one or more final compounds for *in vivo* or clinical testing.

- 5 A pharmaceutical composition comprising a rhomboid modulator, for example an enhancer or inhibitor, may be administered to individuals, for example for the treatment (which may include preventative treatment) of a pathogenic infection or a condition associated with or
- 10 mediated by Rhomboid activity, for example a cardiovascular disorder, including disorders associated with blood coagulation, an inflammatory disorder, or a cancer condition.
- 15 Cardiovascular disorders include disorders such as cardiac myxoma, acute myocardial infarction, stroke, in particular hemorrhagic stroke, ischaemic (coronary) heart disease, atherosclerosis, myocardial ischaemia (angina) and disorders associated with blood coagulation such as
- 20 cerebral thrombosis, cerebral embolism, coronary artery thrombolysis, arterial and pulmonary thrombosis and embolism, and various vascular disorders such as peripheral arterial obstruction, deep vein thrombosis, disseminated intravascular coagulation syndrome, thrombus
- 25 formation after artificial blood vessel operation or after artificial valve replacement, re-occlusion and re-stricture after coronary artery by-pass operation, re-occlusion and re-stricture after PTCA (percutaneous transluminal coronary angioplasty) or PTCR (percutaneous
- 30 transluminal coronary re-canalization) operation and thrombus formation at the time of extracorporeal circulation.

Inflammatory disorders include allergy, asthma, atopic dermatitis, Crohn's disease, Felty's syndrome, gingivitis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, psoriasis, rheumatic fever, 5 rheumatoid arthritis, skin inflammatory diseases, spondylitis, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis and inflammation caused by sepsis or ischaemia.

10 Cancer conditions include cancers, (e.g., histocytoma, glioma, glioblastoma, astrocyoma and osteoma) including lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, oral cancer, colon cancer, breast cancer, oesophageal cancer, ovarian carcinoma, prostate 15 cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, skin cancer and brain cancer.

Other disorders mediated by rhomboid activity include 20 diabetes, disorders of peripheral nervous system, pneumonia, adult respiratory distress syndrome, chronic renal failure and acute hepatic failure.

An aspect of the present invention provides a modulator, 25 for example an inhibitor of Rhomboid protease activity, or composition comprising a said modulator, isolated and/or obtained by a method described herein. Modulators are described in more detail above.

30 Another aspect of the invention provides a chimeric polypeptide which is proteolytically cleavable by a Rhomboid polypeptide, said polypeptide comprising an a core domain which has a rhomboid cleavable TMD sequence linked to an heterogenous upstream tag sequence, the

core domain sequence not being susceptible to cleavage by mammalian metalloproteases.

Chimeric substrate polypeptides are described in more
5 detail above.

Another aspect of the invention provides a nucleic acid encoding a chimeric substrate polypeptide as described above.

10

Nucleic acid encoding a chimeric substrate polypeptide may be provided as part of a replicable vector, particularly any expression vector from which the encoded polypeptide can be expressed under appropriate
15 conditions, and a host cell containing any such vector or nucleic acid. An expression vector in this context is a nucleic acid molecule including nucleic acid encoding a polypeptide of interest and appropriate regulatory sequences for expression of the polypeptide.

20

Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other
25 sequences as appropriate.

A nucleic acid construct which comprises a nucleic acid sequence encoding a chimeric substrate polypeptide, may include an inducible promoter operatively linked to the
30 nucleic acid sequence. This allows control of expression, for example, in response to an applied stimulus.

The term "inducible" as applied to a promoter is well understood by those skilled in the art. In essence,

expression under the control of an inducible promoter is "switched on" or increased in response to an applied stimulus (which may be generated within a cell or provided exogenously). The nature of the stimulus varies
5 between promoters. Whatever the level of expression is in the absence of the stimulus, expression from any inducible promoter is increased in the presence of the correct stimulus. Cells may thus be pre-incubated with a test compound prior to the induction of rhomboid
10 expression.

Many examples of inducible promoters will be known to those skilled in the art (e.g. Tet on/Tet off system, BD Biosciences).

15

Vectors may be plasmids, viral e.g. 'phage, or phagemid, as appropriate. For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory
20 Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current
25 Protocols in Molecular Biology, Ausubel et al. eds. John Wiley & Sons, 1992.

Systems for cloning and expression of polypeptides in a variety of different host cells are well-known. Suitable
30 host cells include bacteria, eukaryotic cells such as mammalian and yeast, and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells

and many others. A common, preferred bacterial host is *E. coli*.

The introduction of nucleic acid into a host cell, which
5 may (particularly for *in vitro* introduction) be generally
referred to without limitation as "transformation", may
employ any available technique. For eukaryotic cells,
suitable techniques may include calcium phosphate
transfection, DEAE-Dextran, electroporation, liposome-
10 mediated transfection and transduction using retrovirus
or other virus, e.g. vaccinia or, for insect cells,
baculovirus. For bacterial cells, suitable techniques
may include calcium chloride transformation,
electroporation and transfection using bacteriophage.

15 Marker genes such as antibiotic resistance or sensitivity
genes may be used in identifying clones containing
nucleic acid of interest, as is well known in the art.

20 The introduction may be followed by causing or allowing
co-expression from the nucleic acid, e.g. by culturing
host cells (which may include cells actually transformed
although more likely the cells will be descendants of the
transformed cells) under conditions for co-expression of
25 the coding sequences, so that the encoded polypeptides
are produced.

Another aspect of the present invention provides a host
cell comprising nucleic acid encoding a chimeric
30 substrate polypeptide, as described herein. A host cell
may comprise an expressed membrane-bound chimeric
substrate polypeptide as described herein.

The nucleic acid may be integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with
5 standard techniques. The nucleic acid may be on an extra-chromosomal vector within the cell.

A host cell as described above may further comprise a heterologous nucleic acid encoding a rhomboid
10 polypeptide, as described above. Suitable rhomboid encoding nucleic acid may be comprised in an expression vector.

A host cell may thus comprise a heterologous Rhomboid
15 polypeptide and a heterologous substrate polypeptide as described herein.

Other aspects of the invention relate to the use of such nucleic acids, vectors and host cells in a method of
20 screening for rhomboid activity, for example in a method described herein.

Methods described herein may also be useful in isolating and/or purifying rhomboid cleavage products. A method for
25 obtaining a cleavage product of a rhomboid polypeptide may comprise:

- (a) contacting a rhomboid polypeptide and a substrate polypeptide in the presence of one or more non-rhomboid proteases,
30 wherein said substrate polypeptide comprises a core domain which has a rhomboid cleavable TMD sequence linked to a heterogenous upstream tag sequence, the core domain sequence not being susceptible to cleavage by the one or more non-rhomboid proteases, and;

(b) contacting said medium with a specific binding member which binds to said tag sequence, and

(c) isolating/purifying soluble polypeptide fragment bound to said specific binding member.

5

Following isolation, the fragment may be investigated further, for example, the fragment may be sequenced.

Suitable specific binding members include antibodies or,
10 when a polyHis tag is used, NiNTA.

Aspects of the present invention will now be illustrated with reference to the accompanying figures described below and experimental exemplification, by way of example
15 and not limitation.

The skilled person will understand that the invention may be carried out with various combinations and sub-combinations of the features described above, and all
20 these combinations and sub-combinations, whether or not specifically described or exemplified, are encompassed by the invention.

Further aspects and embodiments will be apparent to those
25 of ordinary skill in the art. All documents mentioned in this specification are hereby incorporated herein by reference.

Figure 1 shows reporter (substrate) constructs used for
30 rhomboid assays: (a) GFP/TGF α /Spi/TGF α . (b) SEAP/TGF α /Spi/TGF α (c) GFP/6H/Spi/TGF α (d). SEAP/6H/Spi/TGF α .

Figure 2a illustrates the difference between the products generated by a rhomboid cleavage compared to those made by endogenous metalloproteases. The extracellular domain and SPITZ transmembrane domain of the substrate are shown and the location of the membrane is shaded.

Figure 2b shows the principle of the capture assay.

Figure 3 shows total SEAP production in 48h transfection supernatants performed in 6 well plates.

Figure 4 shows the specific capture of rhomboid cleavage product using various concentrations of capture antibody.

Figure 5 shows capture assay results to show the selective capture of rhomboid/SEAP fusion products from large-scale transfection supernatants in the presence or absence of Batimastat (BB).

Examples

Materials and Methods

Constructs

All constructs were generated in the vector pcDNA3.1 (Invitrogen). The construction of TGF α /SPITZ chimeras has been described previously (Urban & Freeman, 2003). The chimera GFP/TGF α /Spi/TGF α (construct a; figure 1) consists of GFP fused to the sequence encoding the first 51 amino acids of human TGF α , Drosophila SPITZ (aa 119-160) and human TGF α C-terminal region (aa 122-160).

To replace the GFP reporter and TGF α signal sequences with SEAP, the SEAP gene and signal sequence was amplified by PCR using the primers "HindSEAP For" (5'-AAGCTTACCACATGCTGCTGCTGCTGCTGCTGCT-3') and "Eco Back" (5'-

ACGGAATTCTGTCTGCTCGAAGCGGCCGGC-3') and pSEAP-2 template DNA (Clontech). The product was cloned into GFP/TGF α /Spi/TGF α using *Hind*III and *Eco*RI restriction sites to generate SEAP/TGF α /Spi/TGF α (construct b, fig.

5 1).

To prepare the construct GFP/6H/Spi/TGF α (construct c, figure 1), PCR primers were designed to amplify the SPITZ TMD and to introduce the MRGS(H)₆ tag sequence immediately upstream. The primers "6HMRGS For" (5'-CGGAATTCATGAGAGGATCGCATCACCATCACCATCACGCGAGCATTGCCAGTGGAGCCA-3') and "BBS Back" (5'-CTGCTATTGTCTTCCCAATCCT-3') were used to PCR amplify the SPITZ TMD using SEAP/TGF α /Spi/TGF α as the template. The product was

10 15 cloned into GFP/TGF α /Spi/TGF α using *Eco*RI and *Bbs*-I restriction sites.

To obtain SEAP/6H/Spi/TGF α (construct d, figure 1), the construct GFP/6H/Spi/TGF α was digested with *Eco*RI and

20 *Rsr*II and the fragment was cloned into SEAP/TGF α /Spi/TGF α using the same sites. In the constructs GFP/6H/Spi/TGF α (construct c, figure 1) and SEAP/6H/Spi/TGF α (construct c, figure 1) the extracellular domain of SPITZ has been deleted.

25 The construction of the expression vector for human Rhomboid RHBDL2 has been described (Urban et al., 2001).

All constructs were verified by sequencing.

30

Transfection of Cos-7 with Rhomboid and substrate reporter constructs

COS-7 cells were grown in DMEM medium containing 10% foetal calf serum (FCS) and antibiotics in 175 cm² growth

area flasks (T175, Sarstedt) in a humidified atmosphere at 37°C/5%CO₂. The cells were passaged when they reached approximately 80% confluency. Transfections were performed in 6-well plates (Costar), 75 cm² (T75) or T175
5 flasks (Sarstedt).

For transfection, the cells were trypsinized, counted and adjusted to 1.0 x 10⁵/ml. Six well plate wells, T75 or T175 flasks were seeded with 2ml, 6ml or 24ml cell
10 suspension respectively. After returning to the incubator for 16h, the cells were transfected with substrate reporter construct alone or together with RHBDL2. Various amounts of substrate and rhomboid construct DNA were used in transfections using FuGENE 6 transfection
15 reagent (Roche). The total DNA was maintained at 1µg for 6 well plate transfections, 2µg for T75 or 4µg for T175 flask transfections by inclusion of PUC18 DNA. For transfection of cells in T175 flasks with substrate construct alone, 2µg of plasmid DNA was prepared and
20 adjusted to a total of 4µg with PUC18 in a volume of 10-15µl H₂O per flask. For co-transfection with Rhomboid, 1.4µg RHBDL2 was mixed with 2µg substrate construct and adjusted to a total of 4µg as above.

25 Prior to transfection, 16µl FuGENE 6 was diluted into 784µl serum-free DMEM and mixed with the prepared plasmid DNA. After incubating at RT for 40min, the mixture was added drop wise to the flask and returned to the incubator for 5-6h. Next the cells were trypsinized and
30 re-seeded into 96-well flat-bottomed tissue culture plates at 1 x 10⁴/well in 100µl volumes and returned to the incubator for 16-18h.

For some experiments, the cells were maintained in flasks without re-seeding. At this time the cells were rinsed once by aspirating and filling the wells with PBS and then replacing the medium with 100 μ l/well serum-free DMEM alone or containing 20 μ M batimastat (British Biotechnology).

For flask cultures the cells were rinsed once with 40ml PBS and the media replaced with 12ml serum-free DMEM +/- batimastat. After incubating for 24h, supernatants were collected and either assayed directly for total SEAP activity or following capture with RGSHis antibody.

Assay for total SEAP reporter activity

Total SEAP activity in the supernatants was assayed in white polystyrene 96-well flat-bottomed plates (Costar) using CSPD[®] chemiluminescent substrate (Phospha-Light[™] assay system, Applied Biosystems) according to the manufacturer's instructions. Briefly, supernatant samples (12.5 μ l) were diluted with 37.5 μ l of dilution buffer in 0.5ml eppendorf tubes and heated to 65°C for 30min to destroy endogenous alkaline phosphatase before adding to the wells. After 5 min at RT, 50 μ l reaction buffer was added to all wells and 20min later luminescence was measured using a microplate luminometer (BMG PolarStar).

Assay for SEAP reporter after capture with immobilised RGS6His antibody

RGS6His monoclonal antibody (Qiagen) was diluted to 2.5 μ g/ml in PBS and 50 μ l/well used to coat white polystyrene 96-well plates (Nunc Maxisorp) overnight at 4°C. The plates were washed 3 times with PBS containing 0.1% Tween 20 (PBS/T) using an automated plate washer. To block the wells, plates were incubated with 100 μ l/well

PBS/T containing 5% non-fat skimmed milk powder (Marvel) for 2h at RT. After 3 washes with PBS/T, 50µl neat transfection, supernatant was added to each test well and incubated for 2h at RT. The plates were washed 5 times and 50µl dilution buffer (Phospha-Light™ assay system, Applied Biosystems) added to all wells, followed by 50µl assay buffer. After 5min, 50µl reaction buffer was added to all wells and 20min later luminescence was measured using a microplate luminometer (BMG PolarStar).

10

Western blot for MRGS/6His tagged polypeptides

Transfection supernatants were analysed by western blot for polypeptides containing the RGS6His tag sequence.

Supernatant samples were subjected to reducing SDS PAGE

15

using a mini gel apparatus (Atto) and transferred to PVDF membranes (Millipore). The membranes were blocked with

PBST containing 5% non-fat skimmed milk powder (Marvel) for 1h at RT. After washing with PBST, the blots were probed with anti-RGS6His monoclonal antibody (Qiagen)

20

diluted 1:2000 in PBST containing 2.5% Marvel for 1h at RT. After further washes the blots were incubated with goat anti-mouse IgG (Fc portion) secondary antibody peroxidase conjugate (Jackson ImmunoResearch) diluted 1:

25,000 for 1h at RT. Finally the blots were washed and

25

incubated with enhanced chemiluminescent substrate (ECL plus, Amersham) according to the manufacturer's instructions before exposure to hyperfilm ECL (Amersham) and development.

30 Results

1. Rhomboid reporter assay based on total SEAP activity in transfection supernatants

A chimeric substrate polypeptide (SEAP/6H/Spi/TGFα; 200ng) comprising a core domain having the TMD of

Drosophila Spitz and an MRGS(H)₆ tag, an extracellular domain having a secreted alkaline phosphatase label and a cytoplasmic domain comprising the TGF α C terminal domain and cytoplasmic sequence from Drosophila Spitz (construct
5 d, figure 1) was expressed in Cos-7 cells alone or with RHBDL2(Rhb, 25ng or 2.5ng), in the presence or absence of batimastat (BB).

Figure 3 shows the total SEAP activity in flask
10 transfection supernatants following transfection with substrate alone or with RHBDL2 in the absence or presence of the hydroxamate inhibitor Batimastat. In the absence of Batimastat, total SEAP activity was highest and unaffected by the inclusion of RHBDL2 DNA in the
15 transfection. However, in the presence of Batimastat, total SEAP activity was reduced, providing indication that the substrate is susceptible to cleavage by endogenous metalloproteases.

20 Following co-transfection of the substrate with RHBDL2 in the presence of Batimastat, total SEAP activity was increased relative to substrate alone indicating rhomboid-specific cleavage. The ratio of chemiluminescence signal in the presence of RHBDL2 to
25 signal for substrate alone was approximately 2:1 when 25ng of RHBDL2 was used to transfect the cells. This example shows that for an assay based on total SEAP reporter activity in the supernatants, inclusion of Batimastat is important in order to suppress the
30 background signal due to metalloprotease-mediated substrate cleavage.

2. Rhomboid reporter assay based on captured SEAP activity in transfection supernatants

The SEAP/6H/Spi/TGF α substrate was designed to be cleaved by RHBDL2 or other rhomboids to release a secreted
5 product that has the tag sequence at or near its C terminus (figures 1 and 2). In contrast, following metalloprotease cleavage the tagged portion is retained in the membrane so the secreted product lacks the tag.

- 10 An assay was designed to selectively capture and measure the rhomboid cleavage product in the medium. In this assay, rhomboid products, which retain the tag, are captured with immobilized tag-specific antibodies. Following washing to remove untagged reporter products,
15 captured reporter is assayed using a chemiluminescent substrate for SEAP (Figure 2).

To this end, ELISA plates were coated with various concentrations of anti-RGS6His monoclonal antibody and
20 incubated with flask transfection supernatants from SEAP/6H/Spi/TGF α substrate construct alone (as a control) or with RHBDL2 (figure 4).

Transfections were performed in T75 flasks using 400ng
25 substrate construct alone or with 100ng rhomboid. The medium was supplemented with 20 μ g/ml Batimastat and harvested at 48h post-transfection.

After washing the plates to remove unbound reporter
30 products, the retained reporter (SEAP) activity was assayed as described above. The results show that in the presence of RHBDL2, SEAP activity was detected in the wells following capture by the anti-RGS6His antibody. The measured activity was dose-dependent with respect to the

antibody concentration used to coat the wells and fell to background levels in uncoated control wells. In contrast, only background reporter signal was detectable at any coating concentration for the control transfection supernatant (substrate alone). The ratio of chemiluminescence signal in the presence of rhomboid to that for the substrate alone was maximal at the highest coating concentration of antibody attempted.

Cos-7 cells were grown in T175 flasks and transfected with 2 μ g of SEAP/6H/Spi/TGF α substrate construct alone or co-transfected with 1.4 μ g rhomboid RHBDL2 (Rhb). The transfected cells were re-seeded into 96-well plates to enable the assay to be used as a high throughput screen for small molecule inhibitors of rhomboid and incubated +/- BB for a further 24h before the supernatants were harvested and tested in the capture assay. In this format, supernatants from 100 μ l cultures were assayed for SEAP after capture with anti-RGS6His-coated ELISA plates (figure 5). Transfected cells were incubated with or without Batimastat for comparison. The results show a signal to background ratio of 133:1 (substrate with rhomboid:substrate alone) in the presence of Batimastat and 129:1 without. Therefore a greatly improved assay performance was obtained. Furthermore, the results show that proteolytic cleavage events due to rhomboid may be assayed in the absence of metalloprotease inhibitors and in a high throughput format. A large reduction in the background signal was attained in the capture assay in comparison to the total SEAP reporter assay and rhomboid-specific cleavage product was specifically determined in the absence of suppression of endogenous metalloproteases.

3. Western blotting with anti-RGSHis antibody

In order to determine the relative sizes of the tagged polypeptides, transfection supernatants were subjected to reducing SDS PAGE followed by transfer to PVDF membranes and western blot with the anti-RGS6His antibody. Cos-7 cells were transfected with SEAP/6H/Spi/TGF α alone or with rhomboid RHBDL2 in T175 flasks before being reseeded into 96 well plates. At 48h post transfection, supernatants were harvested and tested in the western blot procedure for the presence of the tagged substrate product. The results show that a tagged product of approximately 70kDa was present in the supernatants following transfection with rhomboid and substrate together, but not with substrate alone. The size and quantity of the tagged product was not apparently affected by the presence of batimastat in the transfection cultures. Total SEAP activity in the supernatants at the time of harvesting for the substrate alone and substrate plus RHBDL2 transfections were comparable (45561 RLU and 38251 RLU). This provides indication that the substrate alone transfection supernatants contain similar levels of active SEAP reporter product to those with rhomboid, but that rhomboid is necessary to produce the tagged reporter product.

Therefore the western blot results show that metalloproteases cleave the substrate upstream of the tag sequence to generate secreted reporter products that lack the tag sequence. In contrast, tagged products of the expected size were generated in the presence of rhomboid that may also be selectively assayed in the capture assay.

Accession	Gene	Size	Species
P20350	Rhomboid-1		Drosophila Melanogaster
AAK06753	Rhomboid-3		Drosophila Melanogaster
AAK06752	Rhomboid-2		Drosophila Melanogaster
CAA76629(XM_007948, NM_003961,AJ272344)	Rhomboid related protein (RHBL)	438	Homo Sapiens
AAK06754	Rhomboid-4		Drosophila Melanogaster
NP_060291	FLJ20435	292	Homo Sapiens
T16172	F26F4.3	419	C. elegans
AAA02747	AAA02747	325	Saccharum hybrid cultivar H65-7052
S40723	Rhomboid homlog C489B4.2	397	C. elegans
AAF88090	C025417_18	302	Arabidopsis thaliana
AAG51610	C010795_14	317	Arabidopsis thaliana
AAD55606	C008016_16	309	Arabidopsis thaliana
CAB88340	CAB8830	361	Arabidopsis thaliana
AAG28519	PARL	379	Homo sapiens
AE003628	CG5364/Rhomboid-5	1840	Drosophila melanogaster
CAB87281	CAB87281	346	Arabidopsis thaliana
T36724	T36724	297	Streptomyces coelicolor
A55862	AarA	281	Providencia stuartii
BAA12519	YpgP	507	B. subtilis
AAF53172	CG17212/Rhomboid-6	263	Drosophila melanogaster
BAB05140	BH1421	514	Bacillus halodurans
T02735	T9I4.13	372	Arabidopsis thaliana
CAA17304	Rv0110	249	Mycobacterium tuberculosis
T34718	T34718	383	Streptomyces coelicolor
BAB21138	BAB21138	393	Oryza sativa
AAD36164	E001768_13	222	Thermatoga maritime
AAD35669	AE001733_6	235	Thermatoga maritime
T35521	T33521	256	Streptomyces coelicolor
CAC18292	CAC18292	497	Neurospora crassa
T05139	F7H19.260	313	Arabidopsis thaliana
AAG40087	AC079374_1	369	Arabidopsis thaliana
B75109	PAB1920	212	Pyrococcus abyssi
AAK04268	AE006254_9	230	Lactococcus lactis
CAA76716	CAA76716	164	Rattus norvegicus
AAF58598	CG8972/Rhomboid-7	351	Drosophila melanogaster
CAA86933	CAA86933	276	Acinetobacter calcoaceticus
CAA97104	YGR101w/Yeast	346	Saccharomyces cerevisiae

	Rhomboid-1		
AAC07308	AAC07308	227	Aquifex aeolicus
E72574	APE1877	256	Aeropyrum pernix
NP_069844	NP_069844	330	Archaeoglobus fulgibus
AAA58222	AAA58222	274	E. coli
BVECGG	GlpG	276	E. coli
E71025	PH1497	197	Pyrococcus horikoshii
AAK03522	GlpG	291	Pasteurella multocida
G82780	XF0649	224	Xylella fastidiosa
G69772	YdcA	199	Bacillus subtilis
O14362	C30D10.19C	298	Schizosaccharomyces pombe
F82729	XF1054	232	Xylella fastidiosa
BAB04236	BH0517	248	Bacillus halodurans
T34866	T34866	285	Streptomyces coelicolor
A82363	GlpG	277	Vibrio cholerae
I64081	GlpG	192	Haemophilus influenzae
AC026238	AC026238	336	Arabidopsis thaliana
AAH03653	AAH03653	329	Homo sapiens
D71258	GlpG	208	Treponema pallidum
CAB9075	CAB9075	223	Streptococcus uberis
AAK24595	AAK24595	218	Caulobacter crescentus
B83259	PA3086	286	Pseudomonas aeruginosa
C82588	XF2186	206	Xylella fastidiosa
AAG19304	Vng0858c	598	Halobacterium sp.NRC-1
BAB02051	MKP6.17	506	Arabidopsis thaliana
AAG18926	Vng0361c	333	Halobacterium sp.NRC-1
BAB29735	BAB29735	315	Mus musculus
E75328	E75328	232	Deinococcus radiodurans
T49293	T16L24.70	269	Arabidopsis thaliana
CAB83168	CAB83168	392	Schizosaccharomyces pombe
T45666	F14P22.50	411	Arabidopsis thaliana
P53426	B1549_C3_240	251	Mycobacterium leprae
CAC22904I	CAC22904I	214	Sulfolobus solfataricus
T41608	SPCC790.03	248	Schizosaccharomyces pombe
H81375	Cj1003c	172	Campylobacter jejuni
CAC31552	CAC31552	238	Mycobacterium leprae
Q10647	YD37_MYCTU	240	Mycobacterium tuberculosis
NP_015078	Ypl246cp	262	Saccharomyces cerevisiae
S76748	S76748	198	Synechocystis sp.
NM_017821	RHBDL2		Homo sapiens
BE778475	RHBDL3 (partial)		Homo sapiens

Table 1

Accession	Name	Size	Species
Q01083	Spitz	230	D. melanogaster
AAF63381	Keren/Gritz/Spitz-2	217	D. melanogaster
P42287	Gurken	294	D. melanogaster
P01135	TGF- α	160	Homo sapiens
P00533	EGF	1210	Homo sapiens
Q99075	HB-EGF	208	Homo sapiens
JC1467	Betacellulin	178	Homo sapiens
A34702	Amphiregulin	252	Homo sapiens
BAA22146	Epiregulin	169	Homo sapiens
Q03345	Lin-3	438	C. elegans

Table 2

CLAIMS:

- 5 1. A method for identifying and/or obtaining a modulator of a rhomboid polypeptide, which method comprises:
- (a) contacting a rhomboid polypeptide and a substrate polypeptide in the presence of a test compound and one or
10 more non-rhomboid proteases,
wherein said substrate polypeptide comprises a core domain which has a rhomboid cleavable TMD sequence linked to an upstream tag sequence, the core domain sequence not being susceptible to cleavage by the one or more non-
15 rhomboid proteases, and;
- (b) determining the presence or amount in said medium of a soluble polypeptide fragment comprising said tag sequence.
- 20 2. A method according to claim 1 wherein said Rhomboid polypeptide and said substrate polypeptide are co-expressed in a cell.
3. A method according to claim 2 wherein the cell is a
25 mammalian cell.
4. A method according to any one of claims 1 to 3 wherein the presence of the soluble substrate polypeptide is determined by;
- 30 (a) contacting said medium with an specific binding member which binds to said tag sequence, and
(b) determining binding of soluble polypeptide fragment to said binding member.

5. A method according to claim 4 wherein said specific binding member is immobilised.

6. A method according to claim 5 wherein said specific binding member is an antibody.

7. A method according to claim 6 wherein said antibody is immobilised on the surface of microtitre plate.

8. A method according to any one of the preceding claims wherein the substrate polypeptide comprises an extracellular detectable label.

9. A method according to claim 8 wherein the label is secreted alkaline phosphatase.

10. A method according to claim 8 or claim 9 wherein the binding of said polypeptide fragment to said anti-tag antibody is detected by determining the amount of said label bound to the antibody.

11. A method according to claim 10 wherein the amount of said label is determined by contacting said label with a reporter molecule which produces a signal in the presence of said label, and measuring said signal.

12. A method according to claim 11 wherein the signal is light emission.

13. A method according to any one of the preceding claims wherein the tag sequence is positioned 10 amino acid residues or less upstream of said TMD in said core domain.

14. A method according to any one of the preceding claim wherein the tag sequence consists of 30 amino acids or less.
- 5 15. A method according to any one of the preceding claims wherein the tag sequence is MRGS(H)₆.
16. A method according any one of the preceding claims wherein the rhomboid cleavage TMD rhomboid comprises a
10 luminal portion which has the same conformation within the membrane as Spitz residues 140-144.
17. A method according to claim 16 wherein the rhomboid cleavable TMD has a luminal portion which comprises or
15 consists of Spitz residues 140-144 (IASGA).
18. A method according to claim 16 or claim 17 wherein the rhomboid cleavable TMD is a rhomboid ligand TMD.
- 20 19. A method according to claim 18 wherein the rhomboid cleavable TMD is the Spitz TMD.
20. A method according to any one of the preceding claims wherein the substrate polypeptide comprises a
25 cytoplasmic domain, said domain comprising the cytoplasmic domain of TGF α .
21. A method according to any one of the preceding claims wherein the substrate polypeptide comprises a
30 cytoplasmic domain, said domain comprising the cytoplasmic domain of thrombomodulin.

22. A method according to any one of the preceding claims wherein the Rhomboid polypeptide has a sequence shown in Table 1.

5 23. A method according to claim 22 wherein the Rhomboid polypeptide is selected from the group consisting of Drosophila Rhomboid 1, Drosophila Rhomboid 2, Drosophila Rhomboid 3, Drosophila Rhomboid 4, Human RHBDL-1, Human RHBDL-2 and Human RHBDL-3, E. coli glgG, B. subtilis
10 ypqP, P. stuartii A55862 gene product, P. aeruginosa B83259 gene product, S. cerevisiae YGR101w and S. cerevisiae YPL246c.

24. A method according to any one of the preceding
15 claims comprising identifying said test compound as a modulator of Rhomboid protease activity.

25. A method according to claim 24 comprising isolating said test compound.

20

26. A method according to claim 25 comprising synthesising and/or preparing said test compound.

27. A method according to claim 25 or claim 26
25 comprising modifying said compound to optimise the pharmaceutical properties thereof.

28. A method according to any one of claims 24 to 27
30 comprising formulating said test compound in a pharmaceutical composition with a pharmaceutically acceptable excipient, vehicle or carrier.

29. A modulator of Rhomboid protease activity obtained by a method of any one of claims 1 to 23.

30. A method of making a pharmaceutical composition comprising,

5 identifying a compound as a modulator of Rhomboid activity using according to any one of claims 1 to 23, synthesising, preparing or isolating said compound and

10 admixing the compound with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients to formulate or produce said composition.

31. A method according to claim 30 comprising modifying said compound to optimise the pharmaceutical properties
15 thereof.

32. A method according to claim 30 or claim 31 comprising determining the activity of a Rhomboid polypeptide in the presence of said composition.
20

33. A polypeptide which is proteolytically cleavable by a Rhomboid polypeptide, said polypeptide comprising an a core domain which has a rhomboid cleavable TMD sequence linked to an upstream tag sequence, the core domain
25 sequence not being susceptible to cleavage by mammalian metalloproteases.

34. A polypeptide according to claim 33 wherein the tag sequence is positioned 10 amino acid residues or less
30 upstream of said TMD in said core domain.

35. A polypeptide according to claim 33 or 34 wherein the tag sequence consists of 15 amino acids or less.

36. A polypeptide according to claim 35 wherein the tag sequence is MRGS(H)₆

37. A polypeptide according to any one of claims 33 to 5 36 wherein the rhomboid cleavage TMD rhomboid comprises a luminal portion which has the same conformation within the membrane as Spitz residues 140-144.

38. A polypeptide according to claim 37 wherein the 10 rhomboid cleavable TMD has a luminal portion which comprises or consists of Spitz residues 140-144 (IASGA).

39. A polypeptide according to claim 37 or claim 38 15 wherein the rhomboid cleavable TMD is a rhomboid ligand TMD.

40. A polypeptide according to claim 39 wherein the rhomboid cleavable TMD is the Spitz TMD.

20 41. A polypeptide according to any one of claims 33 to 40 wherein the substrate polypeptide comprises an extracellular domain, said domain comprising a detectable label.

25 42. A polypeptide according to claim 41 wherein the label is secreted alkaline phosphatase.

43. A polypeptide according to any one of claims 33 to 42 wherein the substrate polypeptide comprises a 30 cytoplasmic domain, said domain comprising the cytoplasmic domain of thrombomodulin.

44. An isolated nucleic acid encoding a chimeric polypeptide according to any one of claims 33 to 43.

45. An expression vector comprising a nucleic acid according to claim 44.

5 46. A host cell comprising an expression vector according to claim 45 or a chimeric polypeptide according to any one of claims 33 to 43.

47. A host cell according to claim 46 further comprising
10 an expression vector comprising a nucleic acid encoding a rhomboid polypeptide.

48. A method for obtaining a cleavage product of a Rhomboid polypeptide, which method comprises:

15 (a) contacting a Rhomboid polypeptide and a substrate polypeptide and one or more non-rhomboid proteases,

wherein said substrate polypeptide comprises a core domain which has a rhomboid cleavable TMD sequence linked
20 to an upstream tag sequence, the core domain sequence not being susceptible to cleavage by the one or more non-rhomboid proteases, and;

(b) contacting said medium with an antibody which binds to said tag sequence, and

25 (c) isolating/purifying soluble polypeptide fragment bound to said antibody.

49. A method according to claim 48 comprising sequencing the polypeptide fragment.



SPITZ/TGF α SUBSTRATE REPORTER CONSTRUCTS

Figure 1

(a) Substrate Cleavage by Metalloproteases vs. Rhomboids



(b) Assay Principle




Figure 2




Figure 3




Figure 4




Figure 5